Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (DE:82W)
FRANKFURT:82W
Holding DE:82W?
Track your performance easily
82W Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.38 - €29.70
Previous Close€29.7
Volume4.76K
Average Volume (3M)1.84K
Market Cap
€6.55B
Enterprise Value€6.32B
Total Cash (Recent Filing)$254.07M
Total Debt (Recent Filing)$11.36M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 03, 2025EPS Estimate
€0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding218,479,114
10 Day Avg. Volume3,882
30 Day Avg. Volume1,837
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)10.25
Price to Sales (P/S)4.14
Price to Cash Flow (P/CF)15.10
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit8.84
Enterprise Value/Ebitda52.97
Forecast
1Y Price Target
€22.96Price Target Upside-22.69% Downside
Rating ConsensusHold
Number of Analyst Covering12
Hims & Hers Health News
Bulls Say, Bears Say
Bulls Say
Personalization And Patient RetentionHIMS has been able to retain more GLP-1 users than the industry average after they start the treatments as HIMS can personalize dosages and offer a titration schedule to minimize side effects.
Revenue And Profitability GrowthHims & Hers reported strong Q3 results, with revenue growth accelerating meaningfully and coming in well ahead of consensus and guidance, and profitability was also well above expectations and the outlook.
Subscriber Growth And Market ExpansionThe core business continues to show strong adoption rates with 3Q subscriber growth increasing 40% year-over-year.
Bears Say
CompetitionAmazon's entrance into these markets signal growing competition for customers and we expect it will impact a) the prices that HIMS can charge; b) HIMS’ ability to grow and capture new customers and c) HIMS’ LTV/CAC.
PricingAmazon is offering much more compelling prices than HIMS on most treatments, posing a threat to HIMS’ core offering.
Regulatory UncertaintyThere is uncertainty around the longer-term opportunity for HIMS to benefit from compounded semaglutide.
---
Ownership Overview
10.47% Insiders
16.50% Mutual Funds
12.44% Other Institutional Investors
37.24% Public Companies and
Individual Investors
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
82W FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was €7.38 and its highest was €29.70 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Mar 03, 2025 which is in 97 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Nov 04, 2024. The company reported €0.307 earnings per share for the quarter, beating the consensus estimate of €0.107 by €0.201.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Overvalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is €0.17.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 210,101,490 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of €0.307 in its last earnings report, beating expectations of €0.107. Following the earnings report the stock price went up 4.522%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Royce & Associates LLC. It holds Hims & Hers Health’s shares valued at 6M.
---
Hims & Hers Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€22.96 (-22.69% Downside)
€22.96 (-22.69% Downside)
Blogger Sentiment
Bullish
DE:82W Sentiment 85%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
281.38%
12-Months-Change
Fundamentals
Return on Equity
26.35%
Trailing 12-Months
Asset Growth
45.52%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
82W Earnings Call
Q3 2024
0:00 / 0:00
---
82W Revenue Breakdown
96.60% Online
3.40% Wholesale
---
82W Stock 12 Month Forecast
Average Price Target
€22.96
▼(-22.69% Downside)
Technical Analysis
Best Analysts Covering 82W
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+113.14%
reiterated a buy rating 7 days ago
Copying Jonna Kim's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +113.14% per trade.
---